Logo

Roche Receives the US FDA's Approval for First CDx to Identify Endometrial Cancer Patients Eligible for Immunotherapy

Share this

Roche Receives the US FDA's Approval for First CDx to Identify Endometrial Cancer Patients Eligible for Immunotherapy

Shots:

  • The US FDA has approved Ventana MMR RxDx panel to identify endometrial cancer patients who are eligible for treatment with GSK’s Jemperli (monothx.) that has received the US FDA’s approval on Apr 22- 2021
  • The CDx provides clinicians with a standardized testing option that uses a comprehensive panel of DNA mismatch repair (MMR) biomarkers tested by immunohistochemistry (IHC)
  • Ventana MMR RxDx panel is the first immunohistochemistry predictive test that provides clinicians access to a fully automated- easy-to-use MMR test to identify patients who benefitted from Jemperli (dostarlimab-gxly)

  Ref: Globe Newswire | Image: Roche 

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions